Clinical trial NCT05237778: Combined Treatment of Nightmares With Targeted Memory Reactivation and Imagery Rehearsal Therapy
Official title: The Nightmare Catcher: Modulating Dreams With Targeted Memory Reactivation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nightmares, REM-Sleep Type
Lead sponsor: University Hospital, Geneva
Sponsor class: OTHER
First posted: 2022-02-14
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: With this protocol, investigators examine whether targeted memory reactivation (TMR), a technique used to strengthen memories, can accelerate remission of nightmare disorder. This protocol uses TMR during REM sleep to strengthen positive memories generated by Imagery Rehearsal Therapy (IRT), a recommended treatment of nightmares. Patients with nightmare disorder are asked to perform an initial IRT session and, while they generate a positive outcome of their recurrent nightmare, half of the patients are exposed to a sound (TMR group), while no such pairing with a sound takes place for the other half (control group). During the next two weeks, all patients perform IRT every evening at home and are exposed to the sound during REM sleep with a wireless headband, which automatically detects sleep stages. Clinical evaluation of the severity of nightmares before and after (2-weeks follow-up and 3-months follow-up) this intervention takes place using the validated Nightmare Frequency Questionnaire (NFQ, primary outcome measure), which retrospectively identifies the frequency of nightmares. We hypothesize that patients treated with IRT and who are exposed, during REM sleep and over 14 nights, to a sound that had previously been associated with the new positive dream scenario of IRT (TMR group), will have more reduced frequency of nightmares compared to participants with stimulation of the same, but non-associated, sound during REM sleep (control group).


Eligibility criteria: Inclusion Criteria:

* Diagnosis of nightmare disorder according to the International Classification of Sleep Disorders (ICSD-3) diagnostic and coding manual
* Patients with at least moderate severity (\>1 episode per week)

Exclusion Criteria:

* severe depression
* insomnia disorder
* psychosis or anxiety disorder
* other sleep disorder (e.g.,obstructive sleep apnea syndrome, restless legs syndrome)
* neurological disease
* use of medications that would be likely to produce nightmares (e.g. hypnotics, β-blockers, amphetamines, antimicrobial agents)
* use of anxiolytics, antipsychotic or antidepressant medication were excluded.

Primary outcomes:
measure: Nightmare Frequency Questionnaire (NFQ)
timeFrame: 2 weeks
measure: Nightmare Frequency Questionnaire (NFQ)
timeFrame: 3 months
Secondary outcomes:
measure: Nightmare Distress Questionnaire (NDQ)
timeFrame: 2 weeks
measure: Beck Depression Inventory (BDI-II)
timeFrame: 2 weeks
measure: Pittsburgh Sleep Quality Index (PSQI)
timeFrame: 2 weeks
measure: Proportion of the emotion 'joy' in dreams
timeFrame: 2 weeks
measure: Proportion of the emotion 'fear' in dreams
timeFrame: 2 weeks
measure: Nightmare Distress Questionnaire (NDQ)
timeFrame: 3 months
measure: Beck Depression Inventory (BDI-II)
timeFrame: 3 months
measure: Pittsburgh Sleep Quality Index (PSQI)
timeFrame: 3 months
Other outcomes:
Locations:
city: Geneva
country: Switzerland
facility: Center for Sleep Medicine, University Hospitals of Geneva
Study officials:
References: